|
|
|
|
☛Overview |
Leadership
Dr. Lingtao Wu, the CEO and co-founder of TA,
previously was an Associate Professor at Children’s Hospital Los Angeles
(CHLA)/University of Southern California Keck School of Medicine. Since 1994,
Dr. Wu has been directing research teams to study human granulopoiesis,
myeloid leukemia, osteosarcoma, hematopoietic stem cell niche, neutrophil
differentiation, neutrophil function, and neutrophil biomarkers. Dr. Wu
has published >40 peer-reviewed scientific articles related
to these important studies in prestigious journals. Some of these
studies have led to important discoveries that form the basis of an
innovative biotherapeutic, which has potential to be translated into
the first-in-human clinical application to generate functional
neutrophils to fight infection. |
|
Copyright |
|
